anmelden
Novavax Aktie
11,20
EUR
+1,91
EUR
+20,62
%
12,48
USD
-0,07
USD
-0,56
%
nachbörslich
Novavax jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 1,54 Mrd. EUR
KGV 2,64Div. Rendite 0,00%WKN A2PKMZ
ISIN US6700024010
Symbol NVAX
AI Analyse
Es gab keine Analysen zu dieser Aktie in den letzten sechs Monaten.
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| AstraZeneca PLC | 9 | 1 | 0 | 158,22 GBP | - |
| Bayer | 7 | 2 | 0 | 56,56 EUR | +28,96% |
| BioNTech (ADRs) | 5 | 1 | 0 | 129,33 USD | +32,46% |
| CanSino Biologics Inc. Registered Shs -A- | 0 | 0 | 0 | - | - |
| CureVac | 0 | 0 | 0 | - | - |
| Fresenius Medical Care (FMC) St. | 1 | 5 | 3 | 39,31 EUR | -2,02% |
| Fresenius SE & Co. KGaA | 7 | 1 | 0 | 54,50 EUR | +24,50% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| Inovio Pharmaceuticals Inc | 0 | 0 | 0 | - | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Moderna Inc | 0 | 1 | 0 | 45,00 USD | -77,86% |
| Novartis AG | 1 | 8 | 1 | 120,73 CHF | +3,65% |
| Novavax Inc. | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 2 | 5 | 1 | 27,29 USD | -0,44% |
| Roche Holding AG Inhaber-Partizipationsschein | 2 | 2 | 0 | - | - |
| Sanofi S.A. | 5 | 5 | 0 | 93,53 EUR | +31,60% |
| Sinopharm Group Co Ltd (H) | 0 | 0 | 0 | - | - |
| Valneva | 0 | 0 | 0 | - | - |
